J. Prous

823 total citations
27 papers, 665 citations indexed

About

J. Prous is a scholar working on Molecular Biology, Pharmacology and Surgery. According to data from OpenAlex, J. Prous has authored 27 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pharmacology and 4 papers in Surgery. Recurrent topics in J. Prous's work include Lipoproteins and Cardiovascular Health (3 papers), Cardiac electrophysiology and arrhythmias (3 papers) and Computational Drug Discovery Methods (2 papers). J. Prous is often cited by papers focused on Lipoproteins and Cardiovascular Health (3 papers), Cardiac electrophysiology and arrhythmias (3 papers) and Computational Drug Discovery Methods (2 papers). J. Prous collaborates with scholars based in Spain and United States. J. Prous's co-authors include J. Silvestre, X Rabasseda, M. Bayés, Raquel F. Reinoso, J. Castañer, Peter Revill, M.A. Moral, Courtland Robinson, Nakissa Sadrieh and Luis G. Valerio and has published in prestigious journals such as Toxicology and Applied Pharmacology, Journal of Psychopharmacology and Drug News & Perspectives.

In The Last Decade

J. Prous

26 papers receiving 616 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Prous Spain	12	246	100	96	93	91	27	665
Melvin Reichman United States	16	350 1.4×	44 0.4×	108 1.1×	108 1.2×	72 0.8×	28	852
Babu Subramanyam United States	15	351 1.4×	64 0.6×	82 0.9×	98 1.1×	49 0.5×	35	1.0k
Mario Štefanović Croatia	16	266 1.1×	53 0.5×	48 0.5×	76 0.8×	33 0.4×	85	859
Punit H. Marathe United States	15	246 1.0×	45 0.5×	81 0.8×	220 2.4×	35 0.4×	31	854
David Hicks United States	19	229 0.9×	145 1.4×	220 2.3×	88 0.9×	84 0.9×	50	1.1k
Guowei Zhou China	15	226 0.9×	72 0.7×	66 0.7×	113 1.2×	62 0.7×	44	620
T. Saeki Japan	19	450 1.8×	261 2.6×	94 1.0×	108 1.2×	93 1.0×	60	1.0k
Nancy Chu United States	13	268 1.1×	93 0.9×	41 0.4×	56 0.6×	109 1.2×	23	795
David Hreniuk United States	16	546 2.2×	89 0.9×	75 0.8×	117 1.3×	127 1.4×	28	1.2k
Qiuping Ye China	17	285 1.2×	50 0.5×	38 0.4×	151 1.6×	58 0.6×	62	835

Countries citing papers authored by J. Prous

Since Specialization

Citations

This map shows the geographic impact of J. Prous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Prous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Prous more than expected).

Fields of papers citing papers by J. Prous

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Prous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Prous. The network helps show where J. Prous may publish in the future.

Co-authorship network of co-authors of J. Prous

This figure shows the co-authorship network connecting the top 25 collaborators of J. Prous. A scholar is included among the top collaborators of J. Prous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Prous. J. Prous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Prous, J., et al.. (2013). A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities. Toxicology and Applied Pharmacology. 273(3). 427–434. 23 indexed citations

2.

Silvestre, J., Michael F. O‘Neill, & J. Prous. (2013). Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics. Journal of Psychopharmacology. 28(4). 329–340. 11 indexed citations

3.

Silvestre, J. & J. Prous. (2007). Comparative evaluation of potassium hERG channel blockade byantipsychotics. Methods and Findings in Experimental and Clinical Pharmacology. 29(7). 457–457. 25 indexed citations

4.

Prous, J., et al.. (2007). The story so far in R&D.. PubMed. 20(1). 7–15. 6 indexed citations

5.

Sorbera, L.A., et al.. (2007). The year's new drugs and biologics--2006.. PubMed. 20(1). 17–44. 5 indexed citations

6.

Revill, Peter, M.A. Moral, & J. Prous. (2006). Impaired insulin signaling and the pathogenesis of Alzheimer'sdisease. Drugs of today. 42(12). 785–785. 23 indexed citations

7.

Davies, Siân, et al.. (2005). Phytotherapies for diabetes. Drugs of the Future. 30(12). 1253–1253. 25 indexed citations

8.

Silvestre, J. & J. Prous. (2005). Research on adverse drug events. I. Muscarinic M3 receptor bindingaffinity could predict the risk of antipsychotics to induce type 2diabetes. Methods and Findings in Experimental and Clinical Pharmacology. 27(5). 289–289. 110 indexed citations

9.

Bayés, M., X Rabasseda, & J. Prous. (2004). Gateways to clinical trials.. PubMed. 26(1). 129–11. 169 indexed citations

10.

Reinoso, Raquel F., et al.. (2002). Preclinical pharmacokinetics of statins. Methods and Findings in Experimental and Clinical Pharmacology. 24(9). 593–593. 132 indexed citations

11.

Silvestre, J., et al.. (2002). Experimental approaches to sudy PPARgamma agonists as antidiabeticdrugs. Methods and Findings in Experimental and Clinical Pharmacology. 24(8). 515–515. 17 indexed citations

12.

Reinoso, Raquel F., et al.. (2001). Pharmacokinetic interactions of statins. Methods and Findings in Experimental and Clinical Pharmacology. 23(10). 541–541. 10 indexed citations

13.

Larrínaga, Ainhoa Álvarez Ruiz De, Valter Lombardi, L. Fernández‐Novoa, et al.. (2000). Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics.. PubMed. 36(7). 415–99. 51 indexed citations

14.

Prous, J., et al.. (1998). 546C88. Drugs of the Future. 23(2). 123–123. 2 indexed citations

15.

Prous, J. & J. Castañer. (1992). Etoposide Phosphate Disodium Salt. Drugs of the Future. 17(9). 779–779. 1 indexed citations

16.

Prous, J. & J. Castañer. (1992). Liposomal Flurbiprofen Axetil. Drugs of the Future. 17(9). 788–788. 1 indexed citations

17.

Prous, J. & J. Castañer. (1990). Pioglitazone hydrochloride. Drugs of the Future. 15(11). 1080–1080. 2 indexed citations

18.

Robinson, Courtland, J. Prous, & J. Castañer. (1990). Tenidap sodium. Drugs of the Future. 15(9). 898–898. 19 indexed citations

19.

Prous, J. & J. Castañer. (1980). Beta-(1-naphthyl)alanine. Drugs of the Future. 5(10). 497–497. 1 indexed citations

20.

Prous, J., et al.. (1967). [In vitro passing of ouabain through the jejunum sacs of rats].. PubMed. 23(4). 241–2. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact